Results 1 to 10 of about 44,703 (257)

The BRAF V600E/MEK/ERK/METTL3 positive feedback loop regulates autophagy and promotes stemness and invasiveness in glioblastoma via m6A modification [PDF]

open access: yesJournal of Experimental & Clinical Cancer Research
Background Epithelioid glioblastoma (GBM) is characterized by its highly aggressive behavior and the presence of the BRAF V600E mutation. However, the impact and underlying mechanisms of the BRAF V600E mutation on GBM stemness and invasiveness are ...
Yuan Xie   +17 more
doaj   +2 more sources

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated [PDF]

open access: yesJournal of Translational Medicine, 2020
Background Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the use of specific inhibitors targeting this mutation.
Muna Al Hashmi   +16 more
doaj   +5 more sources

Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification

open access: yesActa Dermato-Venereologica, 2021
BRAF/V600E mutation and other cell growth/growth-control mechanisms are involved in naevogenesis and melanomagenesis. Immunoexpression of BRAF/V600E and other molecules (p16, phosphatase and tensin homologue (PTEN), Ki67, hTERT and Cav3.1 and 3.2 calcium
Sara Moreno   +16 more
doaj   +1 more source

BRAFV600E-Negative Hairy Cell Leukaemia [PDF]

open access: yesCase Reports in Hematology, 2013
Since the initial report of theBRAFV600E mutation in hairy cell leukemia, numerous investigators have demonstrated the presence of this activating mutation in nearly all cases of this disease. A case of hairy cell leukemia is documented with a classical clinical, morphological, immunophenotypic, and cytochemical profile in which theBRAFV600E was not ...
Stephen E. Langabeer   +4 more
openaire   +6 more sources

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. [PDF]

open access: yes, 2014
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors.
Cabrilo, Goran   +12 more
core   +11 more sources

BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage

open access: yesBMC Neurology, 2021
Background The effects of BRAF non-V600E and BRAF V600E on the outcomes and the molecular characteristics of adult glioma patients are unknown and need to be explored, although BRAF V600E has been extensively studied in pediatric glioma.
Wei Wang   +4 more
doaj   +1 more source

Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma

open access: yesClinical Medicine Insights: Oncology, 2023
Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between
Tri Bui Dang Minh   +15 more
doaj   +1 more source

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas [PDF]

open access: yesFrontiers in Oncology, 2018
Low-grade gliomas (LGG) are the most common central nervous system tumors in children. Prognosis depends on complete surgical resection. For patients not amenable of gross total resection (GTR) new approaches are needed. The BRAF mutation V600E is critical for the pathogenesis of pediatric gliomas and specific inhibitors of the mutated protein, such as
Francesca Del Bufalo   +11 more
openaire   +3 more sources

Relationship between the BRAF V600E and tumor size, lymph node, and distant metastasis in papillary thyroid carcinoma

open access: yesRussian Open Medical Journal, 2022
Aim – This study aimed to analyze the association between B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E and tumor size, lymph node, and distant metastasis (TNM) status on patients with papillary thyroid carcinoma. Material and Methods – This
Edmond Rukmana Wikanta   +4 more
doaj   +1 more source

Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. [PDF]

open access: yesPLoS ONE, 2013
Aberrant activation of MAP kinase signaling pathway and loss of tumor suppressor LKB1 have been implicated in lung cancer development and progression. Although oncogenic KRAS mutations are frequent, BRAF mutations (BRAF(V600E)) are found in 3% of human ...
Elena González-Sánchez   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy